We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

28 hedge funds and large institutions have $14.8M invested in TScan Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

8% more funds holding

Funds holding: 26 → 28 (+2)

0.03% more ownership

Funds ownership: 50.23% → 50.26% (+0.03%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

49% less capital invested

Capital invested by funds: $29M → $14.8M (-$14.2M)

Holders
28
Holders Change
+2
Holders Change %
+7.69%
% of All Funds
0.45%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
7
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
NW
NewEdge Wealth
Pennsylvania
+$224K
2
NM
Newtyn Management
New York
+$73.6K
3
Millennium Management
Millennium Management
New York
+$47.2K
4
Northern Trust
Northern Trust
Illinois
+$27.6K
5
Renaissance Technologies
Renaissance Technologies
New York
+$24.5K

Top Sellers

1
WP
Woodline Partners
California
-$203K
2
TCM
Tang Capital Management
California
-$106K
3
MAM
Marquette Asset Management
Minnesota
-$88K
4
Morgan Stanley
Morgan Stanley
New York
-$54.9K
5
UBS Group
UBS Group
Switzerland
-$5.99K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$4.32M – – –
BlackRock
2
BlackRock
New York
$2.35M +$321 +131 +0%
DMC
3
Deer Management Company
New York
$1.93M – – –
AI
4
Alphabet Inc
California
$1.65M – – –
DF
5
DC Funds
Virginia
$977K – – –
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$853K – – –
TCM
7
Tang Capital Management
California
$798K -$106K -43,260 -8%
Vanguard Group
8
Vanguard Group
Pennsylvania
$412K +$21.2K +8,638 +3%
NM
9
Newtyn Management
New York
$375K +$73.6K +30,000 +15%
TCM
10
Tekla Capital Management
Massachusetts
$326K – – –
BCM
11
Bridgeway Capital Management
Texas
$187K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$163K -$557 -227 -0.2%
NW
13
NewEdge Wealth
Pennsylvania
$142K +$224K +91,463 New
Morgan Stanley
14
Morgan Stanley
New York
$65.4K -$54.9K -22,395 -35%
DIM
15
DC Investments Management
Virginia
$55.1K – – –
Millennium Management
16
Millennium Management
New York
$31K +$47.2K +19,244 New
LPL Financial
17
LPL Financial
California
$26.4K +$4.91K +2,000 +13%
PFMU
18
Privium Fund Management (UK)
United Kingdom
$24.5K – – –
CC
19
Cannell Capital
Wyoming
$22.7K – – –
State Street
20
State Street
Massachusetts
$21.8K – – –
Prudential Financial
21
Prudential Financial
New Jersey
$20.9K +$4.41K +1,800 +16%
Northern Trust
22
Northern Trust
Illinois
$17.4K +$27.6K +11,245 New
Renaissance Technologies
23
Renaissance Technologies
New York
$16K +$24.5K +10,000 New
TRCT
24
Tower Research Capital (TRC)
New York
$10K +$520 +212 +4%
UBS Group
25
UBS Group
Switzerland
$1.55K -$5.99K -2,441 -71%
1
2

TCRX Hedge Fund Activity: Q4 2022 in Review

28 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q4 2022, worth a combined $14.8M — down 49% from $29M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new TCRX positions and 3 closed out — a net gain of 2 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was NewEdge Wealth, opening a new position worth an estimated $224K. The largest seller was Woodline Partners, exiting entirely with an estimated $203K sold.

  • 28 institutional investors held TScan Therapeutics (TCRX) as of Q4 2022, up from 26 in Q3 2022.
  • Funds reported $14.8M of TScan Therapeutics stock for Q4 2022, down 49% quarter-over-quarter.
  • 5 funds opened new TScan Therapeutics positions in Q4 2022 and 3 closed out, a net change of +2 holders.
  • The largest TScan Therapeutics buyer in Q4 2022 was NewEdge Wealth, an estimated $224K added.
  • The largest TScan Therapeutics seller in Q4 2022 was Woodline Partners, an estimated $203K sold.

Based on aggregated 13F filings for Q4 2022.